Open company graph database — free web & API
Login

Eisai Israel Ltd.

エイズアイ・イスラエル株式会社AliasEisai Co., Ltd.Alias
Ticker
—
Listed market
—
Country
Japan
Employees (consolidated)
10,917
Related companies
10
§01

Basic information

BASIC
Head office
4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088, JapanSources
Chief executive
Haruo NaitoSources
Capital
44,986 JPY
Employees (non-consolidated)
2,998 people
Employees (consolidated)
10,917 people
Start date
1941-12-06
End date
§02

Websites

1 DOMAINS
§03

Business

6
Research and developmentSourcesmanufactureSourcessale and import and export of pharmaceuticalsSourcesbusinessContentsName1SourcesbusinessContentsName2SourcesbusinessContentsName3Sources
§04

Related companies

10 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Arteryex Corporation
Econavista
Eisai China Inc.
Eisai Europe Ltd. Sources
Shareholder
Eisai America, Inc.
Eisai Innovation, Inc.
Eisai Korea Inc.
Wei Cai Pharmaceuticals Co., Ltd.
HI-Eisai Pharmaceutical, Inc.
Limited Liability Company Eisai
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

89 EVENTS

Eisai's founder, Toyoji Naito, was born on August 15 in Ito, a village in Fukui, central Japan. He was the sixth child and third son of Kikuji Naito and his wife, Fuji.Sources

Sakuragaoka Laboratory Co., Ltd. launched the vitamin E product Juvela through Tanabe Motosaburo Store Co., Ltd. Its chocolate‑brown coating, "hard outside, soft inside" pellets and stylish packaging attracted much attention at the time. Juvela became the laboratory's first success. Sakuragaoka Laboratory Co., Ltd. launched Sampon, Japan's first sanitary tampon, through Tanabe Motosaburo Store Co., Ltd.Sources

World War II began.Sources

Nihon Eisai Co., Ltd., the immediate predecessor of Eisai Co., Ltd., was established in Saitama, eastern Japan. "Origin of the Eisai Logomark"Sources

Sakuragaoka Laboratory Co., Ltd. and Nihon Eisai Co., Ltd. merged under the name Nihon Eisai Co., Ltd.Sources

World War II ended.Sources

Nihon Eisai Co., Ltd.'s contraceptive suppository Sampoon, researched and developed during Japan's postwar baby boom, received official approval from the Japanese government. "Eisai Advertising Through the Years". Nihon Eisai Co., Ltd. launched the cardiotonic Neophyllin in Japan.Sources

Nihon Eisai Co., Ltd. launched the high‑dosage vitamin B1 and B2 product Chocola BB Tablets in Japan. Nihon Eisai Co., Ltd. launched the motion sickness remedy Travelmin in Japan.Sources

The company changed its name from Nihon Eisai Co., Ltd. to Eisai Co., Ltd., as it is known today. "Origin of the Eisai Logomark"Sources

Eisai rolled out its first three‑year mid‑term plan. Eisai's Head Office building was completed in Tokyo.Sources

Eisai opened its Taipei Office (now part of Eisai Taiwan Inc.), the company's first overseas branch, in Taiwan. Eisai was publicly listed in the First Section of both the Tokyo and Osaka Stock Exchanges. Gastrointestinal remedies Saclon and Saclon Tablets, recognizable for their distinct green hue even today, were launched in Japan.Sources

Toyoji Naito received the Japan Marketing Award, which recognizes people who have made a significant contribution to marketing and advertising in Japan. The Tokyo Olympics took place.Sources

The Kawashima Plant is completed in Gifu, central Japan. Kawashima Plant opening ceremony. Founder Toyoji Naito is appointed as chairman and Yuji Naito as company president. A three-tier representative director system is introduced: Chairman Toyoji Naito, President Yuji Naito, and Executive Vice President Tatsuo Naito.Sources

Youda Co., Ltd. is established as a pharmaceutical imports subsidiary in Taiwan.Sources

PT Eisai Indonesia is established as a pharmaceutical manufacturing and sales subsidiary in Indonesia. Toyoji Naito resigns as representative director and chairman to assume director and honorary chairman roles.Sources

Toyoji opens the Naito Museum of Pharmaceutical Science and Industry, Japan's first pharmaceutical museum, in Gifu.Sources

The first oil crisis occurs due to conflict in the Middle East.Sources

Eisai (Malaysia) Sdn. Bhd. and Hi-Eisai Pharmaceutical Inc. are established as pharmaceutical sales subsidiaries in Malaysia and the Philippines, respectively. Metabolic cardiotonic : Neuquinon : is launched in Japan.Sources

Naturally derived vitamin E product : Juvelux : is launched in Japan.Sources

Eisai's founder Toyoji Naito passes away at age 89. Peripheral neuropathy treatment : Methycobal : is launched in Japan.Sources

Eisai Asia Regional Services Pte. Ltd. is established as a sales support and management services subsidiary in Singapore.Sources

Eisai U.S.A. Inc. is established as a chemical and pharmaceutical machinery sales subsidiary in California, the United States. The Misato Plant commences pharmaceutical manufacturing in Saitama. Large-scale automated sugar-coating equipment (pan diameter of up to 170 cm) at the Misato Plant.Sources

The Tsukuba Research Laboratories open in Ibaraki, eastern Japan.Sources

Eisai Chemical Co., Ltd. (now Eisai's Kashima Plant) is established in Ibaraki to manufacture active pharmaceutical ingredients (APIs).Sources

Gastritis and gastric ulcer treatment : Selbex : is launched in Japan.Sources

Eisai has supported of the Health and Medical Care Contributions Awards, which are presented to healthcare professionals who have contributed significantly to improving access to healthcare in difficult-to-reach areas from 1987 to 2015.Sources

Eisai rolls out its first five-year mid-term plan.Sources

Eisai Research Institute of Boston, Inc. (now the Boston Research Institute) is established as a discovery research subsidiary in Massachusetts, the United States.Sources

President Yuji Naito steps down from office and assumes the role of chairman; Vice President Haruo Naito is appointed president of Eisai.Sources

"Passing of the baton" from Yuji Naito : (right) : to Haruo Naito : (left)Sources

Eisai America, Inc. is established as a clinical research subsidiary in New Jersey, the United States.Sources

Eisai Europe Ltd. is established as a clinical research subsidiary in London, the United Kingdom.Sources

Eisai Machinery GmbH is established as a pharmaceutical machinery sales subsidiary in Cologne, former West Germany.Sources

Eisai (Thailand) Marketing Co., Ltd. is established as a pharmaceutical sales subsidiary in Bangkok, Thailand.Sources

Haruo Naito announces Eisai's "Commitment to Innovation."Sources

Eisai London Research Laboratories, Ltd. is established as a discovery research subsidiary attached to University College London in the United Kingdom.Sources

Japan's bubble economy bursts.Sources

Eisai Hong Kong Co., Ltd. is established as a pharmaceutical sales subsidiary in Hong Kong.Sources

The Beijing Representative Office is established in Beijing, China.Sources

Shenyang Eisai Pharmaceutical Co., Ltd. is established as a Chinese–foreign contractual joint venture in pharmaceutical manufacturing and sales in Shenyang, China.Sources

Eisai celebrates its 50th anniversary.Sources

Eisai adopts its current Corporate Mission and Corporate Objective.Sources

Eisai Corporation of North America is established as a holding company in New Jersey, the United States.Sources

Eisai London Research Laboratories, Ltd. is completed in the United Kingdom to form an Eisai Group multipolar R&D network spanning Japan, America and Europe.Sources

Eisai London Research Laboratories opening ceremony in 1993 attended by the United Kingdom's Princess Royal, Princess AnneSources

Eisai Inc. is established as a pharmaceutical sales subsidiary in New Jersey, the United States.Sources

Eisai Ltd. is established as a pharmaceutical sales subsidiary in London, the United Kingdom.Sources

Eisai Deutschland GmbH is established as a pharmaceutical sales subsidiary in Frankfurt, Germany.Sources

Eisai S.A. is established as a pharmaceutical sales subsidiary in Paris, France.Sources

Eisai Suzhou Pharmaceutical Co., Ltd. is established as a pharmaceutical manufacturing and sales subsidiary in Jiangsu, China.Sources

Elmed Eisai Co., Ltd. is established as a generic drug sales subsidiary in Tokyo.Sources

Eisai Manufacturing Ltd. is established as a pharmaceutical manufacturing subsidiary in Hertfordshire, the United Kingdom.Sources

Eisai acquires Morphotek Inc., a bioventure specialized in antibody research, in the United States.Sources

Eisai Pharmatechnology & Manufacturing Pvt. Ltd. is established as an API/formulation manufacturing and R&D subsidiary in Vizag, India.Sources

Eisai SA/NV is established as a pharmaceutical sales subsidiary in Brussels, Belgium.Sources

Eisai acquires MGI Pharma Inc., an oncology biopharmaceutical company in the United States.Sources

Eisai Machinery Shanghai Inc. is established as a subsidiary in Shanghai, China to provide marketing support and maintenance services for pharmaceutical machinery.Sources

Rheumatoid arthritis treatment Humira is launched in Japan.Sources

Eisai GesmbH is established as a pharmaceutical sales subsidiary in Vienna, Austria.Sources

The European Knowledge Centre (now EMEA Knowledge Centre) opens as a European strategic base in Hertfordshire, the United Kingdom.Sources

EMEA Knowledge Centre: The Eisai Product Creation Systems organizational structure is introduced Group-wide to reflect a new focus on patient-oriented R&D.Sources

Haruo Naito is appointed as president of the International Federation of Pharmaceutical Manufacturers & Associations.Sources

The Eisai Knowledge Centre, India opens as a manufacturing and process research base in Vizag, India.Sources

The Koishikawa Knowledge Center opens in Tokyo and receives the 24th Nikkei New Office Promotion Award.Sources

Koishikawa Knowledge Center: Eisai Limited is established as a pharmaceutical sales subsidiary in Ontario, Canada.Sources

Production headquarters transforms to a global “Eisai Demand Chain Systems” structure to reflect a new “demand-driven” customer satisfaction focus in drug manufacturing.Sources

Eisai (Suzhou) Trading Co., Ltd. is established as a pharmaceutical trading subsidiary in Jiangsu, China.Sources

Anticancer agent Halaven is launched in the United States.Sources

Eisai signs a statement with the World Health Organization (WHO) to supply a primary lymphatic filariasis medicine free of charge.Sources

H3 Biomedicine Inc. is established as a research subsidiary in the United States.Sources

The Great East Japan Earthquake strikes.Sources

Eisai rolls out its sixth mid-term plan, “HAYABUSA.”Sources

Eisai Participações Ltda. is established as a pharmaceutical sales subsidiary in São Paulo, Brazil.Sources

Halaven is launched in Europe and Japan.Sources

Eisai Laboratorios S. de R.L. de C.V. is established as a pharmaceutical sales subsidiary in Mexico City, Mexico.Sources

Eisai signs the London Declaration, which is committed to the elimination of ten neglected tropical diseases by 2020.Sources

Haruo Naito is appointed as president of the Federation of Pharmaceutical Manufacturers' Associations of Japan (FPMAJ).Sources

Antiepileptic agent Fycompa is launched in Europe.Sources

Eisai Israel Ltd. is established as a pharmaceutical sales subsidiary in Tel Aviv, Israel.Sources

Eisai and Biogen amend collaboration agreements on : ADUHELM : .Sources

Eisai makes Arteryex Inc., a company that plans and develops software, its subsidiary.Sources

Eisai Pharmaceuticals Africa (Pty) Ltd is established as a pharmaceutical sales subsidiary in Johannesburg, South Africa.Sources

Eisai signs the public private partnership “Kigali Declaration” for eliminating neglected tropical diseases.Sources

Deep Human Biology Learning (DHBL), a new R&D organization, commences full-scale operation.Sources

Alzheimer’s disease treatment : LEQEMBI : is granted accelerated approval and launched in the United States.Sources

Eisai commits funding to the 3rd phase of Global Health Innovative Technology Fund.Sources

LEQEMBI : is granted traditional approval by the FDA.Sources

Theoria technologies Co., Ltd. is established as a digital business company in Tokyo, Japan.Sources

LEQEMBI : is launched in Japan.Sources

§07

News

109 ARTICLES

Environmental Action Across the Eisai GroupSources

Guided by its human health care (hhc) concept, Eisai Group aims to improve health and well-being and contribute to social good. Recognizing that people’s health depends on a healthy global environment, the group works to reduce the environmental impact of its business and encourage employees to deepen their understanding of environmental issues and act on it.

Learning Global Health Through Everyday TopicsSources

Eisai supports global health through initiatives such as improving access to medicines in developing countries and developing treatments for neglected tropical diseases. During summer vacation, Sustainability Department members visited after-school childcare facilities to help children learn about global health.

A Closer Look at São Tomé and PríncipeSources

The feature introduces São Tomé and Príncipe through the impressions of Miwa Jindo of Eisai’s Sustainability Department, who attended a May 29, 2026 meeting there. The meeting launched the final surveillance activities under the WHO program to eliminate lymphatic filariasis.

Eisai Retained in All Six GPIF ESG IndicesSources

For 2026, Eisai remains a constituent of all six Japanese equity ESG indices adopted by Japan’s Government Pension Investment Fund (GPIF). The company was also selected for the FTSE4Good Index Series and MSCI Selection Indexes.

Eisai’s Mycetoma Efforts in SDGs TalkSources

Eisai’s efforts to develop treatments for mycetoma were featured in “SDGs Talk,” a global health discussion series published by the GHIT Fund. The fund supports the development of drugs, vaccines, and diagnostics for malaria, tuberculosis, and neglected tropical diseases through public-private partnerships.

Final Surveillance for Filariasis EliminationSources

São Tomé and Príncipe has begun final surveillance toward eliminating lymphatic filariasis as a public health problem. Eisai has supported the initiative since 2018, including by providing diethylcarbamazine (DEC) tablets free of charge, and attended a launch meeting on May 29, 2026.

Eisai Selected for SOMPO Sustainability IndexSources

Eisai Co., Ltd. was selected for the SOMPO Sustainability Index for FY2026, continuing its listing since the index began in FY2012. The index comprises approximately 300 companies recognized for ESG initiatives, with constituents reviewed annually based on environmental and ESG management surveys.

Eisai Wins Top Score in CDP Supplier Engagement AssessmentSources

Eisai received the highest rating of "Supplier Engagement Leader" in the CDP Supplier Engagement Assessment. This is the second consecutive award, following last year, and in 2025 it was selected for the A-list in the areas of "Climate Change" and "Water Security".

Kawashima Plant Wins Gifu Decarbonization AwardSources

Eisai’s Kawashima Plant in Kakamigahara, Gifu Prefecture, was selected for the newly established Gifu Decarbonization Top Runner Award in recognition of its proactive greenhouse gas reduction efforts. Launched by Gifu Prefecture in fiscal 2025, the award aims to accelerate reductions in greenhouse gas emissions from business activities in the prefecture.

Eisai Wins Human Capital Awards for Third YearSources

Eisai was selected for “Thought Leaders of Human Capital 2025” and the “Human Capital Management Excellence 2025 Gold Award,” marking its third consecutive year of recognition. The awards were based on the Human Capital Survey 2025, which involved 316 companies and organizations.

§09

Sources & updates

SOURCES
↑